Evidence map›Paper›PMID 40755109›Full record

ReviewCurrent Alzheimer research2025

Integration of Neuroimaging and Molecular Biomarkers in the Diagnosis of Alzheimer's Disease and Frontotemporal Dementia: The Promise of fMRI.

Joanna Poszwa, Bartosz Słowikowski, Wojciech Owecki, Oliwia Szymanowicz, Pawel P Jagodzinski, Wojciech Kozubski, Jolanta Dorszewska

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current Alzheimer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joanna PoszwaLaboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Bartosz SłowikowskiDepartment of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.
Wojciech OweckiLaboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Oliwia SzymanowiczLaboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Pawel P JagodzinskiDepartment of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, Poznan, Poland.
Wojciech KozubskiDepartment of Neurology, Poznan University of Medical Sciences, Poznan, Poland.
Jolanta DorszewskaLaboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDementia is a set of acquired and progressive neuropsychiatric disorders. The most common types of dementia include Alzheimer's Disease (AD) and Frontotemporal Dementia (FTD). Early intravital diagnosis of both types of dementia is difficult. Both molecular and neuroimaging markers are important for the diagnosis of different types of dementia.

methodsThis review employed freely accessible databases, including PubMed, Google Scholar, and ScienceDirect, using keywords such as molecular parameters, neuroimaging factors, dementia, FTD, Alzheimer's disease, and fMRI.

resultsAmong the molecular markers of dementia, there are parameters common to its various types and enabling their differentiation. These parameters include both genetic and biochemical factors. Markers include genetic factors that help differentiate AD DISCUSSION: The review encompasses the basic diagnostic criteria for AD and FTD dementia, as well as molecular and neuroimaging parameters important for the intravital diagnosis of these dementias. It seems that the use of fMRI can contribute to both early diagnosis and early introduction of targeted treatment in developing dementia. Although it is not yet widely used clinically, its diagnostic value is increasingly recognized.

conclusionThe benefits of fMRI studies complementing molecular markers in the diagnosis of dementia were highlighted.

Indexed as

Alzheimer DiseaseBrainFrontotemporal DementiaMagnetic Resonance ImagingNeuroimagingBiomarkersHumansBiomarkersAlzheimer’s diseasedementiafMRI. *FTDMolecular parametersneuroimaging factors

Identifiers

PMID40755109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.